Loading
PPP2R1A is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
The PR65 subunit of protein phosphatase 2A serves as a scaffolding molecule to coordinate the assembly of the catalytic subunit and a variable regulatory B subunit. Upon interaction with GNA12 promotes dephosphorylation of microtubule associated protein TAU/MAPT. Required for proper chromosome segregation and for centromeric localisation of SGO1 in mitosis.
CIViC holds 2 clinical evidence items and 0 assertions across 2 variants, naming Ipilimumab/Nivolumab Regimen and Durvalumab/Tremelimumab Regimen. Open Targets scores its association with cancer at 0.81 (direct and indirect evidence; datatypes affected pathway 0.89, literature 0.89, genetic association 0.00, somatic mutation 0.97, animal model 0.69). IntOGen calls it a driver in 11 cohorts (10 activating, 1 loss-of-function), covering Adenoid Cystic Carcinoma, Colorectal Adenocarcinoma, Ovarian Epithelial Tumour, Small Cell Lung Cancer, Endometrial Carcinoma, Uterine Carcinosarcoma/Uterine Malignant Mixed Mullerian Tumour and others.
In plain words · PPP2R1A is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
PPP2R1A is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
The PR65 subunit of protein phosphatase 2A serves as a scaffolding molecule to coordinate the assembly of the catalytic subunit and a variable regulatory B subunit.
No product in this corpus aims at PPP2R1A yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA PPP2R1A: RNA low tissue specificity; no normal tissue stained high. Distribution: 8 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Endometrial cancer, Colorectal cancer, Ovarian cancer, Salivary gland cancers, Thyroid cancer, Lung cancer (all types), Skin cancer (all types) and more); Open Targets associates it with 1 specific cancer type at or above 0.5 (endometrial cancer). (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P30153; CIViC gene PPP2R1A; IntOGen PPP2R1A; Human Protein Atlas PPP2R1A tissue; Open Targets ENSG00000105568 associations
First described 1989. Earliest sequence paper UniProt cites for the protein: Walter et al, Proc. Natl. Acad. Sci. U.S.A, 1989, "Molecular cloning and sequence of cDNA encoding polyoma medium tumor antigen-associated 61-kDa protein". Source.
Sources: HGNC HGNC:9302 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P30153 (protein name, function text, keywords and locations (REST API)); CIViC gene PPP2R1A (2 evidence items, 0 assertions, 2 variants; diseases: Ovarian Clear Cell Carcinoma (GraphQL API, CC0)); Open Targets ENSG00000105568 (association with cancer (MONDO_0004992) 0.81; per-cancer scores at or above 0.5: colorectal cancer 0.54, gastric cancer 0.50, ovarian cancer 0.51, endometrial cancer 0.68, melanoma 0.55, skin cancer 0.55 (GraphQL API, CC0)); IntOGen PPP2R1A (driver in 11 cohorts (Act 10, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
The PR65 subunit of protein phosphatase 2A serves as a scaffolding molecule to coordinate the assembly of the catalytic subunit and a variable regulatory B subunit. Upon interaction with GNA12 promotes dephosphorylation of microtubule associated protein TAU/MAPT. Required for proper chromosome segregation and for centromeric localisation of SGO1 in mitosis. Together with RACK1 adapter, mediates dephosphorylation of AKT1 at 'Ser-473', preventing AKT1 activation and AKT-mTOR signalling pathway. Dephosphorylation of AKT1 is essential for regulatory T-cells (Treg) homeostasis and stability. Part of the striatin-interacting phosphatase and kinase (STRIPAK) complexes. Location: Cytoplasm; Nucleus; Chromosome; Chromosome, centromere (UniProt). Locus 19q13.41 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
No normal tissue stained high.
No cancer sample stained medium or high.
HPA PPP2R1A tissue · HPA PPP2R1A pathology · HPA protein class: Essential proteins
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"PPP2R1A" OR ABSTRACT:"PPP2R1A" OR TITLE:"protein phosphatase 2 scaffold subunit Aalpha" OR ABSTRACT:"protein phosphatase 2 scaffold subunit Aalpha" OR TITLE:"Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform" OR ABSTRACT:"Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform" OR TITLE:"PR65A" OR ABSTRACT:"PR65A" OR TITLE:"PP2A-Aalpha" OR ABSTRACT:"PP2A-Aalpha" OR TITLE:"PP2AA" OR ABSTRACT:"PP2AA") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PPP2R1A, not a curated reading list.
Shares Thyroid cancer, Skin cancer (all types), CIViC, IntOGen.
Shares Thyroid cancer, Skin cancer (all types), IntOGen, Gastric & gastro-oesophageal junction cancer.
Shares Salivary gland cancers, Skin cancer (all types), IntOGen, Lung cancer (all types).
Shares Thyroid cancer, Endometrial cancer, CIViC, IntOGen.
Shares Thyroid cancer, Endometrial cancer, Open Targets Platform, Colorectal cancer.
Shares Salivary gland cancers, Skin cancer (all types), IntOGen, Lung cancer (all types).
Shares Salivary gland cancers, CIViC, IntOGen, Ovarian cancer.
Shares Thyroid cancer, CIViC, Open Targets Platform, Colorectal cancer.